The DOI matches its Crossref record.
A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease
Abstract
Visilizumab is a humanized anti-CD3 monoclonal antibody characterized by a mutated IgG2 isotype, lack of binding to Fcγ-receptors, and ability to induce apoptosis selectively in activated T cells. To test pharmacokinetics, safety, and immunosuppressive activity of visilizumab, 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in a phase 1 study. Six patients were given 7 doses of visilizumab (0.25 or 1.0 mg/m2) on days 1, 3, 5, 7, 9, 11, and 13. Because multiple doses of 1 mg/m2 caused delayed visilizumab accumulation and prolonged lymphopenia, the next 11 patients received a single dose of 3.0 mg/m2 on day 1. GVHD improved in all patients; 15 were evaluable through day 42. Multiple dosing resulted in 1 of 6 complete responses (CRs) and 5 partial responses (PRs), but all 6 patients died at a median of 87 days after starting visilizumab therapy. Single dosing resulted in 6 of 9 CRs, 3 PRs, and 7 of 11 patients surviving after 260 to 490 days (median, 359 days; P = .03). There were no allergic reactions and 3 grade 1 acute infusional toxicities. Plasma Epstein-Barr virus (EBV) DNA titers more than 1000 copies/mL and posttransplant lymphoproliferative disease (PTLD) developed in 2 of the first 7 patients. Based on rising EBV DNA titers, 5 of the next 10 patients were given the B cell–specific monoclonal antibody, rituximab. EBV DNA became undetectable and no overt PTLD developed. Visilizumab is well tolerated and has activity in advanced GVHD. A phase 2 study incorporating preemptive therapy for PTLD is warranted to determine the efficacy of visilizumab in GVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
Self-citationRituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., et al. (2006) · Blood · doi:10.1182/blood-2006-01-0233 · Cited by 452
How I treat refractory acute GVHD
Deeg, H. J. (2007) · Blood · doi:10.1182/blood-2006-12-041889 · Cited by 407
Self-citationCD3-specific antibodies: a portal to the treatment of autoimmunity
Chatenoud, L., & Bluestone, J. A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2134 · Cited by 388
Metadata
- Authors
- Carpenter, P. A., Appelbaum, F. R., Corey, L., Deeg, H. J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J., Slattery, J., Levitt, D., Storb, R., Woolfrey, A., & Anasetti, C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-04-15
- Volume
- 99
- Issue
- 8
- Pages
- 2712-2719
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2103796478
- Cited by
- 172
- References
- 0
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. https://app.cochat.ai/papers/10.1182/blood.v99.8.2712
- The paper
- Carpenter, P. A., Appelbaum, F. R., Corey, L., Deeg, H. J., Doney, K., Gooley, T., Krueger, J., Martin, P., Pavlovic, S., Sanders, J., Slattery, J., Levitt, D., Storb, R., Woolfrey, A., & Anasetti, C. (2002). A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. https://doi.org/10.1182/blood.v99.8.2712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.